论文部分内容阅读
目的 探讨肾上腺素β3受体基因W6 4R多态性与原发性高血压患者苯那普利降压疗效之间是否存在相关性。方法 在安徽省安庆及霍邱地区人群中筛选原发性高血压患者 1170名 ,所有患者予苯那普利 10mg每日一次口服 15d ,测定其用药前后的血压 ,并进行肾上腺素 β3受体基因W6 4R基因型测定 ,观察其血压下降情况与基因型的关系。结果 (1)在中国南方汉族原发性高血压患者中 ,ADRβ3W6 4R多态性位点的基因型频率是 :WW基因型 72 .8%、WR基因型 2 5 .4 %、RR基因型 1.8%。 (2 )苯那普利 10mg每日一次口服 15d ,女性患者收缩压下降水平在ADRβ3W6 4R多态性位点各基因型之间差异具显著性 ,WR RR基因型者比WW基因型者收缩压下降少3.4 9mmHg(P =0 .0 3)。 (3)药物治疗 15d后女性患者第 16天收缩压降至 14 0mmHg以下、舒张压降至 90mmHg以下或下降幅度≥ 15 %的达标率 ,WR RR基因型低于WW基因型 (OR =0 .6 5 ,P <0 .0 5 )。结论 在女性原发性高血压患者肾上腺素 β3受体基因W6 4R多态性与原发性高血压患者苯那普利降压疗效之间存在相关性 ,可能为预测苯那普利降压疗效的一个预报因子 ,指导临床用药。
Objective To investigate whether there is a correlation between the W6 4R polymorphism of adrenergic β3 receptor gene and the antihypertensive effects of benazepril in patients with essential hypertension. Methods A total of 1170 essential hypertension patients were selected from the population of Anqing and Huoqiu in Anhui Province. All patients were given benazepril 10mg orally daily for 15 days. The blood pressure was measured before and after administration, and the adrenaline β3 receptor gene W6 4R genotype was measured to observe the relationship between blood pressure drop and genotype. Results (1) The frequencies of ADRβ3W6 4R polymorphism loci were 72.8% in WW genotype, 25.4% in WR genotype and 1.8 in RR genotype in Chinese Han patients with essential hypertension in South China %. (2) Benazepril 10mg orally daily for 15 days, female patients with systolic blood pressure decreased in the ADRβ3W6 4R polymorphism loci genotype differences were significant, WR RR genotype than the WW genotype systolic blood pressure A decrease of 3.4 9 mmHg decreased (P = .0 3). (3) After 15 days of treatment, the systolic blood pressure of female patients decreased to 14 0mmHg on the 16th day, the compliance rate of diastolic blood pressure dropped below 90mmHg or the rate of decrease ≥ 15%, and the WR RR genotype was lower than that of the WW genotype. 6 5, P <0. 05). Conclusion There is a correlation between the W6 4R polymorphism of adrenergic β3 receptor gene and the antihypertensive effect of benazepril in patients with essential hypertension. It may be used to predict the antihypertensive efficacy of benazepril A predictor of clinical medication.